Proteostasis Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2007)
Status: Acquired by Yumanity (2020)

Organization Overview

First Clinical Trial
2016
NCT02846142
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Proteostasis Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

pti-428 (6 trials)

Drugs in Phase 1 Trials (4)

ethinyl estradiol (Estinyl) (1 trial)

norgestrel (Ovral) (1 trial)

pti-801 (3 trials)

pti-808 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 5